NVS 126.55 ▲ 0.06% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Novartis AG

    NYSE: NVS · Real-Time Price · USD
    126.55
    0.08 (0.06%)
    At close: Aug 29, 2025, 3:59 PM
    126.28
    -0.21%
    Pre-market: Sep 02, 2025, 04:54 AM EDT
    0.06%
    Bid 119.1
    Market Cap 244.98B
    Revenue (ttm) 54.63B
    Net Income (ttm) 9.62B
    EPS (ttm) 6.86
    PE Ratio (ttm) 18.45
    Forward PE 13.67
    Analyst Hold
    Ask 126.9
    Volume 761,055
    Avg. Volume (20D) 1,519,366
    Open 126.25
    Previous Close 126.47
    Day's Range 126.05 - 126.94
    52-Week Range 96.06 - 128.03
    Beta 0.55

    About NVS

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol NVS
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for NVS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Novartis AG is scheduled to release its earnings on Oct 28, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    -3.25%
    Novartis shares are trading lower following a Q2 s... Unlock content with Pro Subscription
    4 months ago
    +3.98%
    Novartis shares are trading higher after the company announced it will commit $23 billion to expand US manufacturing over the next 5 years.
    news image

    2 weeks ago · fool.com

    Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm

    Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar compe...

    news image

    2 weeks ago · fool.com

    2 Dividend Stocks to Buy and Hold

    We've seen several investing trends sweep through Wall Street in recent years, from excitement about the cannabis market to the artificial intelligence (AI) industry that's now dominating headlines. S...

    news image

    3 weeks ago · wsj.com

    Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease

    The pharma company said the drug has the potential to become the first and only targeted treatment approved for patients with Sjoegren's disease.

    news image

    3 weeks ago · investors.com

    Avidity Biosciences Rockets As Novartis Reportedly Mulls A Takeover Deal

    Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.

    news image

    3 weeks ago · reuters.com

    Novartis weighs deal for biotech Avidity Biosciences, FT reports

    Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter

    news image

    1 month ago · wsj.com

    Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

    Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

    1 month ago · youtube.com

    Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

    Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

    1 month ago · youtube.com

    President Trump demands drugmakers slash prices within 60 days

    CNBC's Joe Kernen reports on the latest news.

    news image

    1 month ago · reuters.com

    Trump pressures 17 pharma CEOs to cut US drug prices

    U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...

    news image

    1 month ago · cnbc.com

    Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

    President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...

    Add to Watchlist